Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Aug;66(2):405–407. doi: 10.1038/bjc.1992.278

Phase I study of intra-arterial interleukin-2 in squamous cell carcinoma of the head and neck.

M E Gore 1, P Riches 1, K MacLennan 1, M O'Brien 1, J Moore 1, G Dadian 1, A Lorentzos 1, R Garth 1, E Moskovic 1, D Archer 1, et al.
PMCID: PMC1977791  PMID: 1503916

Full text

PDF
405

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bock S. N., Lee R. E., Fisher B., Rubin J. T., Schwartzentruber D. J., Wei J. P., Callender D. P., Yang J. C., Lotze M. T., Pizzo P. A. A prospective randomized trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapy. J Clin Oncol. 1990 Jan;8(1):161–169. doi: 10.1200/JCO.1990.8.1.161. [DOI] [PubMed] [Google Scholar]
  2. Cortesina G., De Stefani A., Galeazzi E., Cavallo G. P., Jemma C., Giovarelli M., Vai S., Forni G. Interleukin-2 injected around tumor-draining lymph nodes in head and neck cancer. Head Neck. 1991 Mar-Apr;13(2):125–131. doi: 10.1002/hed.2880130208. [DOI] [PubMed] [Google Scholar]
  3. Cotran R. S., Pober J. S. Effects of cytokines on vascular endothelium: their role in vascular and immune injury. Kidney Int. 1989 Apr;35(4):969–975. doi: 10.1038/ki.1989.80. [DOI] [PubMed] [Google Scholar]
  4. Damle N. K., Doyle L. V., Bender J. R., Bradley E. C. Interleukin 2-activated human lymphocytes exhibit enhanced adhesion to normal vascular endothelial cells and cause their lysis. J Immunol. 1987 Mar 15;138(6):1779–1785. [PubMed] [Google Scholar]
  5. Fleischmann J. D., Shingleton W. B., Gallagher C., Ratnoff O. D., Chahine A. Fibrinolysis, thrombocytopenia, and coagulation abnormalities complicating high-dose interleukin-2 immunotherapy. J Lab Clin Med. 1991 Jan;117(1):76–82. [PubMed] [Google Scholar]
  6. Grimm E. A., Mazumder A., Zhang H. Z., Rosenberg S. A. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982 Jun 1;155(6):1823–1841. doi: 10.1084/jem.155.6.1823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hardy J. R., Moore J., Lorentzos A., Ellis E., Jameson B., Gore M. E. Infectious complications of interleukin 2 therapy. Cytokine. 1990 Jul;2(4):311–311. doi: 10.1016/1043-4666(90)90034-q. [DOI] [PubMed] [Google Scholar]
  8. Henney C. S., Kuribayashi K., Kern D. E., Gillis S. Interleukin-2 augments natural killer cell activity. Nature. 1981 May 28;291(5813):335–338. doi: 10.1038/291335a0. [DOI] [PubMed] [Google Scholar]
  9. Lissoni P., Tancini G., Rovelli F., Cattaneo G., Archili C., Barni S. Serum interleukin-2 levels in relation to the neuroendocrine status in cancer patients. Br J Cancer. 1990 Nov;62(5):838–839. doi: 10.1038/bjc.1990.389. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Malkovský M., Loveland B., North M., Asherson G. L., Gao L., Ward P., Fiers W. Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes. Nature. 1987 Jan 15;325(6101):262–265. doi: 10.1038/325262a0. [DOI] [PubMed] [Google Scholar]
  11. Mavligit G. M., Zukiwski A. A., Gutterman J. U., Salem P., Charnsangavej C., Wallace S. Splenic versus hepatic artery infusion of interleukin-2 in patients with liver metastases. J Clin Oncol. 1990 Feb;8(2):319–324. doi: 10.1200/JCO.1990.8.2.319. [DOI] [PubMed] [Google Scholar]
  12. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  13. Rosenberg S. A., Lotze M. T., Yang J. C., Aebersold P. M., Linehan W. M., Seipp C. A., White D. E. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg. 1989 Oct;210(4):474–485. doi: 10.1097/00000658-198910000-00008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Waldmann T. A., Goldman C. K., Robb R. J., Depper J. M., Leonard W. J., Sharrow S. O., Bongiovanni K. F., Korsmeyer S. J., Greene W. C. Expression of interleukin 2 receptors on activated human B cells. J Exp Med. 1984 Nov 1;160(5):1450–1466. doi: 10.1084/jem.160.5.1450. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES